Fed. Circ. Backs Toss Of AbbVie's Humira License Suit
The appeals court ruled that even if MedImmune Ltd.’s patent was found invalid, it would still be unclear whether AbbVie Inc. must continue to pay royalties under the license agreement, which is governed by British law.
Citing U.S. Supreme Court precedent that...
To view the full article, register now.